Dharmacon Establishes Genome-Wide RNAi Global Initiative with Research Institutes
News Oct 07, 2005
Dharmacon, Inc. has announced the formation of the Genome-Wide RNAi Global Initiative, an alliance of leading international biomedical research centers.
The initial goal of the Global Initiative is to accelerate the scientific and medical discoveries made possible by the recent availability of the first complete siRNA library to target genes across the entire human genome.
Genome-wide siRNA libraries have the potential to fundamentally change biological research by dramatically increasing scientists' ability to understand disease mechanisms and facilitating faster drug discovery and development.
The Global Initiative will provide a forum for member institutions to share research protocols, establish experimental standards and develop mechanisms for exchanging and comparing screening data.
This ongoing interaction between Global Initiative members is expected to help researchers optimize high-throughput human- genome-wide siRNA screening and accelerate drug discovery.
Global Initiative founding members include The Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital and Samuel Lunenfeld Research Institute at Mount Sinai Hospital, both with The University of Toronto; Cancer Research UK (CRUK) funded scientists at the London Research Institute and the Institute of Cancer Research (ICR); The German Cancer Research Center (DKFZ); UNMC Eppley Cancer Center at the University of Nebraska Medical Center; Netherlands Cancer Institute (NKI); The Scottish Centre for Genomic Technology and Informatics based at the University of Edinburgh Medical School (GTI); University of Texas Southwestern Medical Center and Yale University.
University of Cambridge scientists at the Cambridge Institute for Medical Research and MRC Cancer Cell Unit, and The University of Texas M. D. Anderson Cancer Center are also expected to join the Global Initiative, pending final institutional approval.
“We welcome the opportunity to collaborate with our fellow researchers to accelerate the adoption and enhance the utility of this revolutionary technology,” said Dr. Michael White, professor of cell biology at the University of Texas Southwestern Medical Center.
“The genome-wide siRNA library provides an unprecedented opportunity to explore the molecular fulcrums of biological systems in an unbiased format - largely free from the constraints of preconceived notions or assumptions.”
“We are pioneering a 'pathway biology' approach to biomedical research,” said Professor Peter Ghazal, director of The University of Edinburgh Medical School's Scottish Centre for Genomic Technology and Informatics (GTI).
“Access to the genome-wide siRNA library will enable us to systematically and selectively explore the role of individual components in our molecular networks, dramatically enhancing the power of this holistic approach.”
The founding members encompass a broad spectrum of biomedical research interests.
A number have announced their intention to house the genome-wide siRNA library in central high-throughput screening facilities to increase its availability throughout their organizations, and many will focus their initial efforts on using the library for cancer research.
Professor René Bernards of the Netherlands Cancer Institute, noted, “The genome-wide siRNA library will be an important tool for identification of genes involved in cancer.”
“We expect this work to complement our earlier screens using viral vector libraries.”
“Genome-wide siRNA libraries represent a fundamental tool in functional genomic research, and we anticipate that the interaction between the Global Initiative members will be very valuable in helping to speed the progress of biomedical knowledge that RNAi is making possible.”
Dr. Michael Boutros of the German Cancer Research Center (DKFZ) added, “Our recently published work on RNAi screening in Drosophila cells demonstrated the power of conducting unbiased genome-wide screens.”
“With this new library we are now able to conduct genome-wide screens in human cells - a critically important step in understanding the biological basis of human cancers.”
“We expect this Global Initiative to foster interaction between scientists from a variety of disciplines to discuss insights and issues obtained by using this important new tool as part of their ongoing research programs.”
“Dharmacon is fostering the formation of this Global Initiative to enable leading researchers from around the world to share their experiences and exchange ideas on how best to realize the potential of Dharmacon's siARRAY® Human Genome Library, the first complete human genome-wide siRNA library available to researchers,” said William S. Marshall, Ph.D., vice president of technology and business development for Fisher Biosciences.
“This library already represents an unprecedented tool for functional genomic research, and we believe its potential will be greatly expanded by the focused collaboration between leading international laboratories that the Global Initiative is designed to encourage.”
“We look forward to collaborating with these world-class investigators in pursuit of our shared goal of using RNAi technology to advance science and medicine.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.